Clinical Trial Update: Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan [Phase 4]

View source ↗

Summary

A Phase 4 study investigating bosentan for pulmonary arterial hypertension secondary to idiopathic pulmonary fibrosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Pulmonary Arterial Hypertension

Drugs mentioned

• Bosentan (Bosentan)

Snippet

Sponsor: Rajan Saggar | Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis | Phase 4 | Status: WITHDRAWN